Decreased expression of SOCS-3 mRNA in breast cancer with lymph node metastasis

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 33-39

  Nakagawa, Tsuyoshi ^a   Iida, Satoru ^a   Osanai, Takayuki ^a   Uetake, Hiroyuki ^a   Aruga, Tomoyuki ^a   Toriya, Youichi ^a   Takagi, Yoko ^a   Kawachi, Hiroshi ^a   Sugihara, Kenichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; Signal transducers and activators of transcription; Suppressors of cytokine signaling

Indexed keywords

MESSENGER RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 38749118957     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.1.33     Document Type: Article

References (38)

1. Bromberg JF, Wrzeszczynska MH, Devgan G, et al: Stat3 as an oncogene. Cell 98: 295-303, 1999.
2. Shuai K and Liu B: Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3: 900-911, 2003.
3. Bowman T, Garcia R, Turkson J, et al: STATs in oncogenesis. Oncogene 19: 2474-2488, 2000.
4. Niu G, Wright KL, Huang M, et al: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
5. Arany I, Chen SH, Megyesi JK, et al: Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett 199: 83-89, 2003.
6. Watson CJ and Miller WR: Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 71: 840-844, 1995.
7. Dolled-Filhart M, Camp RL, Kowalski DP, et al: Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9: 594-600, 2003.
8. Dhir R, Ni Z, Lou W, et al: Stat3 activation in prostatic carcinomas. Prostate 51: 241-246, 2002.
9. Wei D, Le X, Zheng L, et al: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22: 319-329, 2003.
10. Benekli M, Xia Z, Donohue KA, et al: Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99: 252-257, 2002.
11. Hsieh FC, Cheng G and Lin J: Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 335: 292-299, 2005.
12. Kusaba T, Nakayama T, Yamazumi K, et al: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 58: 833-838, 2005.
13. Zhang H, Wang S, Zhang YC, et al: Correlation between Stat3 signal transduction pathway and expression of cyclooxygenase-2 in colorectal cancer cells. Zhonghua Yi Xue Za Zhi 85: 2899-2904, 2005.
14. Horiguchi A, Oya M, Shimada T, et al: Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol 168: 762-765, 2002.
15. Masuda M, Suzui M, Yasumatu R, et al: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62: 3351-3355, 2002.
16. Kusaba T, Nakayama T, Yamazumi K, et al: Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 15: 1445-1451, 2006.
17. Dien J, Amin HM, Chiu N, et al: Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol 169: 633-642, 2002.
18. O'Shea J, Gadina M and Schreiber R: Cytokine signaling in 2002 new surprises in the Jak/Stat pathway. Cell 109: S121-S131, 2002.
19. David S. Aaronson, Curt M and Horvath CM: A road map for those who don't know JAK-STAT. Science 296: 1653-1655, 2002.
20. Emanuelli B, Peraldi P, Filloux C, et al: SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275: 15985-15991, 2000.
21. Fujimoto M and Naka T: Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 24: 659-666, 2003.
22. Mora LB, Buettner R, Seigne J, et al: Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62: 6659-6666, 2002.
23. De Vos J, Jourdan M, Tarte K, et al: JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 109: 823-828, 2000.
24. Yoshikawa H, Matsubara K, Qian GS, et al: SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28: 29-35, 2001.
25. Rottapel R, Ilangumaran S, Neale C, et al: The tumor suppressor activity of SOCS-1. Oncogene 21: 4351-4362, 2002.
26. Weber A, Hengge UR, Bardenheuer W, et al: SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24: 6699-6708, 2005.
27. Oshimo Y, Kuraoka K, Nakayama H, et al: Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer 112: 1003-1009, 2004.
28. Sobin LH and Wittekind CL (eds.): TNM Classification of Malignant Tumors. 6th edition. John Wiley & Sons, New York, NY, 2002.
29. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
30. Lord RV, Salonga D, Danenberg KD, et al: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 4: 135-142, 2000.
31. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001.
32. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408, 2001.
33. Chapman RS, Lourenco PC, Tonner E, et al: Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13: 2604-2616, 1999.
34. He B, You L, Uematsu K, et al: SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100: 14133-14138, 2003.
35. Sutherland KD, Lindeman GJ, Choong DY, et al: Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23: 7726-7733, 2004.
36. Yang B, Guo M, Herman JG, et al: Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 163: 1101-1107, 2003.
37. Niwa Y, Kanda H, Shikauchi Y, et al: Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24: 6406-6417, 2005.
38. Veronesi U, Paganelli G, Galimberti V, et al: Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349: 1864-1867, 1997.